Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 15/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 10/20 | 0.85 |
| ▸ | FLT1 | P17948 | 9/20 | 0.85 |
| ▸ | BCR | P11274 | 6/20 | 0.71 |
| ▸ | KDR | P35968 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3542686 | 0.96 | ABL1 (0.92) | ABL1FGFR1FLT1BCRKDR | |
| SCHEMBL3538437 | 0.94 | ABL1 (1.00) | ABL1FGFR1FLT1BCRKDR | |
| SCHEMBL3533705 | 0.94 | ABL1 (1.00) | ABL1FGFR1FLT1BCRKDR | |
| SCHEMBL3535571 | 0.94 | ABL1 (0.98) | ABL1FGFR1FLT1BCRKDR | |
| SCHEMBL13548658 | 0.91 | ABL1 (0.85) | ABL1FGFR1FLT1BCRKDR | |
| SCHEMBL13548646 | 0.90 | ABL1 (1.00) | ABL1FGFR1FLT1BCRKDR | |
| SCHEMBL3532275 | 0.89 | ABL1 (0.85) | ABL1FGFR1FLT1BCRKDR | |
| SCHEMBL3542252 | 0.88 | ABL1 (0.86) | ABL1FGFR1FLT1BCRKDR | |
| SCHEMBL3533317 | 0.88 | ABL1 (0.87) | ABL1FGFR1FLT1BCRKDR | |
| SCHEMBL5866762 | 0.88 | ABL1 (0.87) | ABL1FGFR1FLT1BCRKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060205941-A1 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. | 2006-09-14 | — | — | US | claimed |
| US-7642278-B2 | Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642278-B2 | Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642278-B2 | Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-7642275-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20060205941-A1 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. | 2006-09-14 | — | — | US | disclosed |
| US-20060079564-A1 | Indazole benzimidazole compounds | CHIRON CORPORATION | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079564-A1 | Indazole benzimidazole compounds | ABL1, ABL2, ALK | ABL1 1/4885FGFR1 886/4885FLT1 2793/4885 |
| US-20060205941-A1 | Histone deacetylase inhibitors | HDAC1, HDAC3, HDAC5 | ABL1 3782/4885FGFR1 2538/4885FLT1 4776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.